Ignite Creation Date:
2024-05-05 @ 11:36 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00080509
Status:
TERMINATED
Last Update Posted:
2010-02-03
First Post:
2004-04-05
Brief Title:
Effectiveness of KOS-862 in the Treatment of Lung Cancer
Sponsor:
Bristol-Myers Squibb
Organization:
Bristol-Myers Squibb
Study Overview
Official Title:
A Phase 2 Study of KOS-862 Administered Intravenously Weekly for 3 Weeks Every 4 Weeks in Patients With Non-Small Cell Lung Cancer Who Have Progressed Following Initial Therapy for Advanced or Metastatic Disease
Status:
TERMINATED
Status Verified Date:
2009-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine whether a potential drug known as KOS-862 or Epothilone D has an effect as a 2nd line treatment in non-small cell lung cancer NSCLC for patients having failed one prior platinum-containing chemotherapy regimen
Detailed Description:
To determine the antitumor activity based on the confirmed objective response rate of KOS-862 administered intravenously weekly for 3 weeks every 4 weeks in patients with non-small cell lung cancer NSCLC whose disease has progressed following initial chemotherapy for advanced or metastatic disease
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None